IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$690.24−10.41 (-1.49%)
Close on Nov 17, 2026Market cap $54.38BP/E 48.5Yield –
IDEXX Laboratories ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
IDEXX Laboratories's ebitda for the twelve months ending Jun 30, 2026 was $1.61B, up 15.8% year over year. For fiscal 2025 it was $1.51B, up 19.6% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $1.51B in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51B | +19.6% |
| FY2024 | Dec 31, 2024 | $1.26B | +3.8% |
| FY2023 | Dec 31, 2023 | $1.21B | +19.9% |
| FY2022 | Dec 31, 2022 | $1.01B | -2.5% |
| FY2021 | Dec 31, 2021 | $1.04B | +31.1% |
| FY2020 | Dec 31, 2020 | $790.52M | +23.4% |
| FY2019 | Dec 31, 2019 | $640.86M | +11.5% |
| FY2018 | Dec 31, 2018 | $574.51M | +15.8% |
| FY2017 | Dec 31, 2017 | $496.17M | +15.8% |
| FY2016 | Dec 31, 2016 | $428.46M | +16.2% |
| FY2015 | Dec 31, 2015 | $368.87M | +15.6% |
| FY2014 | Dec 31, 2014 | $319.14M | -0.7% |
| FY2013 | Dec 31, 2013 | $321.36M | +2.0% |
| FY2012 | Dec 31, 2012 | $314.97M | +10.7% |
| FY2011 | Dec 31, 2011 | $284.43M | +13.8% |
| FY2010 | Dec 31, 2010 | $249.84M | +10.7% |
| FY2009 | Dec 31, 2009 | $225.74M | +2.4% |
| FY2008 | Dec 31, 2008 | $220.44M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $466.62M | +14.1% |
| Q1 FY2026 | Mar 31, 2026 | $400.27M | +14.2% |
| Q4 FY2025 | Dec 31, 2025 | $354.33M | +20.0% |
| Q3 FY2025 | Sep 30, 2025 | $391.47M | +15.8% |
| Q2 FY2025 | Jun 30, 2025 | $408.82M | +38.1% |
| Q1 FY2025 | Mar 31, 2025 | $350.60M | +6.6% |
| Q4 FY2024 | Dec 31, 2024 | $295.39M | +7.4% |
| Q3 FY2024 | Sep 30, 2024 | $338.03M | +11.1% |
| Q2 FY2024 | Jun 30, 2024 | $295.99M | -8.6% |
| Q1 FY2024 | Mar 31, 2024 | $328.86M | +6.5% |
| Q4 FY2023 | Dec 31, 2023 | $275.04M | +7.8% |
| Q3 FY2023 | Sep 30, 2023 | $304.27M | +11.3% |
| Q2 FY2023 | Jun 30, 2023 | $324.00M | +56.4% |
| Q1 FY2023 | Mar 31, 2023 | $308.73M | +12.3% |
| Q4 FY2022 | Dec 31, 2022 | $255.25M | +12.5% |
| Q3 FY2022 | Sep 30, 2022 | $273.38M | +8.3% |
| Q2 FY2022 | Jun 30, 2022 | $207.19M | -27.2% |
| Q1 FY2022 | Mar 31, 2022 | $274.86M | +0.8% |
| Q4 FY2021 | Dec 31, 2021 | $226.89M | +8.2% |
| Q3 FY2021 | Sep 30, 2021 | $252.43M | +28.5% |
| Q2 FY2021 | Jun 30, 2021 | $284.63M | +31.3% |
| Q1 FY2021 | Mar 31, 2021 | $272.68M | +62.8% |
| Q4 FY2020 | Dec 31, 2020 | $209.66M | +51.7% |
| Q3 FY2020 | Sep 30, 2020 | $196.51M | +21.1% |
| Q2 FY2020 | Jun 30, 2020 | $216.83M | +16.6% |
| Q1 FY2020 | Mar 31, 2020 | $167.53M | +8.4% |
| Q4 FY2019 | Dec 31, 2019 | $138.22M | +1.7% |
| Q3 FY2019 | Sep 30, 2019 | $162.25M | +17.4% |
| Q2 FY2019 | Jun 30, 2019 | $185.90M | +11.7% |
| Q1 FY2019 | Mar 31, 2019 | $154.49M | +15.4% |
| Q4 FY2018 | Dec 31, 2018 | $135.95M | +13.9% |
| Q3 FY2018 | Sep 30, 2018 | $138.23M | +14.1% |
| Q2 FY2018 | Jun 30, 2018 | $166.49M | +16.3% |
| Q1 FY2018 | Mar 31, 2018 | $133.85M | +18.9% |
| Q4 FY2017 | Dec 31, 2017 | $119.33M | +14.7% |
| Q3 FY2017 | Sep 30, 2017 | $121.14M | +11.9% |
| Q2 FY2017 | Jun 30, 2017 | $143.15M | – |
| Q1 FY2017 | Mar 31, 2017 | $112.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $104.07M | – |
| Q3 FY2016 | Sep 30, 2016 | $108.23M | – |
See a number that looks wrong?